The New York Times (9/13, Thomas) reports that the recalls of a lot of Risperdal Consta, (an injectable antipsychotic treatment) and 200,000 bottles of liquid Motrin for infants, have raised new questions about whether Johnson & Johnson “has moved on from its past problems” with quality lapses.
Last week, J & J recalled 200,000 bottles of liquid Motrin for infants because they may contain tiny particles of plastic. Then, on Wednesday, J & J’s pharmaceutical unit, Janssen, informed doctors and patients that it was recalling a lot of Risperdal after routine testing turned up evidence of mold.
While the company said no reports of serious harm were received and the risk to patients in both cases was small, “some experts said the two recalls, announced over such a short span, raised questions about how well the company has improved its oversight after a string of manufacturing problems threatened its image.” As also pointed out by the New York Times, the company has recalled everything from Tylenol to contact lenses and artificial hips in recent years, and is operating under a consent decree with the Food and Drug Administration in which it has promised to overhaul production at three manufacturing plants. One plant, in Fort Washington, Pa., has been closed since 2010.
Zoll, Kranz & Borgess, LLC- Pharmaceutical Drug and Device Litigation Attorneys